First Qtr. Results

Quote

anonymous

Guest
OUCH!!!! Take away the $12.7 million in SQ sales and Conmed declined by 5% vs. prior year. When CH took over Conmed was declining at 1 to 2%. Then under CH it grew to 3% decline. Now the organic business is declining at 5%. SQ is now on board, true. But it cost $265 million to bring it here, and to show any growth at all. The only thing that is growing at a substantial rate is the debt and losses. CH and all his Stryker buddies have done nothing to grow sales, quite the opposite. You just have to wonder how long it will be until the new lady on the board (Aronson) takes CH's job, similar to how CH took Joe C's job?
 






anonymous said:
OUCH!!!! Take away the $12.7 million in SQ sales and Conmed declined by 5% vs. prior year. When CH took over Conmed was declining at 1 to 2%. Then under CH it grew to 3% decline. Now the organic business is declining at 5%. SQ is now on board, true. But it cost $265 million to bring it here, and to show any growth at all. The only thing that is growing at a substantial rate is the debt and losses. CH and all his Stryker buddies have done nothing to grow sales, quite the opposite. You just have to wonder how long it will be until the new lady on the board (Aronson) takes CH's job, similar to how CH took Joe C's job?
Click to expand...

You are wrong about one thing. There is one more thing that is growing and that's CH's exit package when they finally boot that fraud out. But, isn't that package the only reason CH came on board? He told the AI clowns what they wanted to hear and is laughing himself silly that they bought his garbage. Getting rid of anyone associated with the Corasanti's seems to be his only talent.
 






anonymous said:
You are wrong about one thing. There is one more thing that is growing and that's CH's exit package when they finally boot that fraud out. But, isn't that package the only reason CH came on board? He told the AI clowns what they wanted to hear and is laughing himself silly that they bought his garbage. Getting rid of anyone associated with the Corasanti's seems to be his only talent.
Click to expand...

CH sure can keep coming up with excuses. I work on the Linvatec side, so I can't speak of the other Conmed divisions, other than I know their sales are declining too. On the Linvatec side, this new two year old regime hasn't released one new product organically (they've only bought 3 small products that don't even count as M&As). The funny thing is, in the last two years of the old regime they released: Hall 50, Lithium Ion battery platform, Micropower Plus, IM8000 Video, bought Viking 3D Video, and corporately partnered with MTF. Is it just me, or does the old Corasanti/J.D regime look like superstars compared to these new clowns? Think about how excited we were 2 years ago when this whole change went down. What a huge disappointment! You have to keep in mind that all of our major competitors (at least on the ortho side) are growing at a minimum of 5% annually. And we're now declining at 5% annually. That's a pretty big spread.
 






Conmed is on a downward spiral so much that I fear that time is running out. Nothing new in the pipeline, no future, competitors gaining market share. We're a sinking ship with more holes developing each day. Painful decision, its time for me to go.
 






anonymous said:
CH sure can keep coming up with excuses. I work on the Linvatec side, so I can't speak of the other Conmed divisions, other than I know their sales are declining too. On the Linvatec side, this new two year old regime hasn't released one new product organically (they've only bought 3 small products that don't even count as M&As). The funny thing is, in the last two years of the old regime they released: Hall 50, Lithium Ion battery platform, Micropower Plus, IM8000 Video, bought Viking 3D Video, and corporately partnered with MTF. Is it just me, or does the old Corasanti/J.D regime look like superstars compared to these new clowns? Think about how excited we were 2 years ago when this whole change went down. What a huge disappointment! You have to keep in mind that all of our major competitors (at least on the ortho side) are growing at a minimum of 5% annually. And we're now declining at 5% annually. That's a pretty big spread.
Click to expand...
 






you forgot but the 3 new products that the new regime claims for their credit was actually started by the old regime...thats how long it takes to get things done here at conmed!!! And Regurgi-surgiquest....same story...so two years into it and nothing has happened that has changed conmed for the better...your quote is right it is actually worse!! Can't wait to get out of here.
 






anonymous said:
OUCH!!!! Take away the $12.7 million in SQ sales and Conmed declined by 5% vs. prior year. When CH took over Conmed was declining at 1 to 2%. Then under CH it grew to 3% decline. Now the organic business is declining at 5%. SQ is now on board, true. But it cost $265 million to bring it here, and to show any growth at all. The only thing that is growing at a substantial rate is the debt and losses. CH and all his Stryker buddies have done nothing to grow sales, quite the opposite. You just have to wonder how long it will be until the new lady on the board (Aronson) takes CH's job, similar to how CH took Joe C's job?
Click to expand...
 







What did you expect?? Hartman and his crew are a bunch of Stryker Rejects. Total losers! Only ConMed would hire these morons! Their all laughing their way to the Bank!!!
 






The earnings call was a train wreck, CH should be thankful they keep getting easy questions. I got out 3 years ago, I enjoyed my time at Conmed but it became so frustrating to be part of a company with so much potential lose it's way.

Conmed is in a dangerous place now, that Voce letter is ringing very true now!
 
























anonymous said:
OUCH!!!! Take away the $12.7 million in SQ sales and Conmed declined by 5% vs. prior year. When CH took over Conmed was declining at 1 to 2%. Then under CH it grew to 3% decline. Now the organic business is declining at 5%. SQ is now on board, true. But it cost $265 million to bring it here, and to show any growth at all. The only thing that is growing at a substantial rate is the debt and losses. CH and all his Stryker buddies have done nothing to grow sales, quite the opposite. You just have to wonder how long it will be until the new lady on the board (Aronson) takes CH's job, similar to how CH took Joe C's job?
Click to expand...
You know what I don't get is why they raised the revenue target for the year from approx. $765 million to $775 million. They even had the analysts on the call asking about that. If sales continue to fall at a 5% rate on all the business except SQ, which was $720 million in 2015, then those sales will become $684 million in 2016. If SQ does come in at $60 million for the year which is optimistic, then Conmed does $744 million for the year. It will take everything we've got to get to the original forecast. Does this new increased forecast have anything to do with the annual shareholder meeting later this month? Do these big institutional shareholders buy into forecasts like that? Can't you get into some kind of trouble misleading investors the way CH has since the day he took the CEO job with the numbers he's put out and consistently missed? Seems kinda like desperation to me.
 






anonymous said:
You know what I don't get is why they raised the revenue target for the year from approx. $765 million to $775 million. They even had the analysts on the call asking about that. If sales continue to fall at a 5% rate on all the business except SQ, which was $720 million in 2015, then those sales will become $684 million in 2016. If SQ does come in at $60 million for the year which is optimistic, then Conmed does $744 million for the year. It will take everything we've got to get to the original forecast. Does this new increased forecast have anything to do with the annual shareholder meeting later this month? Do these big institutional shareholders buy into forecasts like that? Can't you get into some kind of trouble misleading investors the way CH has since the day he took the CEO job with the numbers he's put out and consistently missed? Seems kinda like desperation to me.
Click to expand...


No. Fuzzy math is permissible.
 






























ConMed will never succeed because it fires people with kaizen approach and half a brain and retains 25 year micromanagers who are insecure and threatened by new talent . ConMed is a classic 60s company , only a few get to rule and the rest of the poppers are supposed to put up and shut up . Old technology and unimpressive people and got rid of most of the great talent and synergy that SurgiQuest brought , sales will continue to decline esp with micromanaging
Managers , very mismanaged esp in hr​
 












Top Bottom
Back
Quote